Standard Bitola Inc. (NASDAQ:LAB) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Peter DeNardo – Investor Relations Michael Egholm – Chief Executive Officer and President Vikram Jog – Chief Financial Officer Conference Call Participants Operator Greetings, and welcome to the Standard BioTools Inc. First Quarter 2022 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Peter DeN ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ (Exact name of registrant as specified in its charter) Delaware 77-0513190 State or other jurisdiction of incorporation or organization I.R.S. Employer Identification No. 2 Tower Place, Suite 2000 South San Francisco, CA 94080 Address of principal executive offices Zip Code FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal yea ...

Financial Highlights - Q4 revenue reached $38.3 million[11] - Q4 product and service margin was 52.7% (GAAP) and 61.8% (Non-GAAP)[11] Market Opportunities and Growth - The total addressable market is estimated to be approximately $7 billion[17] - The total addressable market is projected to grow to approximately $9 billion by 2025[18] - Multiplex Proteomics is estimated to have a CAGR of ~8% from 2020-2025[19] - Next-Gen Sequencing Library Prep is estimated to have a CAGR of ~14% from 2020-2025[19] - Midthroughput Molecular Diagnostics is estimated to have a CAGR of ~9% from 2020-2025[19] - Mass Cytometry market is growing at 10%-plus[25] Market Penetration - Academia and Medical Centers: 19% penetrated today, targeting 30% penetration by 2025[27] - Pharma/Biotech: 8% penetrated today, targeting 30% penetration by 2025[27] - CROs: 1% penetrated today, targeting 10% penetration by 2025[27] - Hospitals/Reference Labs: 0% penetrated today, targeting 5% penetration by 2025[27]

Investor Overview November 2021 Legal Information Forward-looking statements This presentation and the accompanying presentations (including an oral presentation) contain forwardlooking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding: advantages of and prospects for Fluidigm's technologies and products; market opportunities and growth and Fluidigm access to and participation in such markets; revenue growth and profitability ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2021 was $28.5 million, down from $39.9 million in Q3 2020, primarily due to lower COVID-19 revenue and development grants [18] - Base product and service revenue, excluding COVID-19 testing, was $25.6 million, slightly up from $25.1 million year-over-year [18] - GAAP net loss for Q3 2021 was $13.8 million compared to $6 million in Q3 2020, while non-GAAP net loss was $5.4 million compared to a net income of $2.5 million in the prior year [22][23] Business Line Data and Key Metrics Changes - Mass cytometry product and service revenue was $15.8 million, up 5% from Q3 2020 [19] - Microfluidics product and service revenue was $12.1 million, down 40% year-over-year, primarily due to a $7.9 million decline in COVID testing revenue [19] - Service revenue was $6 million, slightly down from $6.1 million in the same period last year [19] Market Data and Key Metrics Changes - Revenue from the Americas declined by 45% to $13 million, driven by lower COVID testing revenue [21] - EMEA revenue grew 14% to $10.1 million, primarily due to improved mass cytometry instrument sales [21] - Asia-Pacific revenue decreased by 27% to $5.4 million, impacted by tax exemption delays in China and lockdowns in Japan [21] Company Strategy and Development Direction - The company is focusing on a three-part strategy: innovation, partnerships, and beachhead expansion [5] - The launch of the Biomark X instrument is part of the strategy to integrate existing technologies and expand market reach [8] - The Board of Directors is reviewing strategic alternatives to maximize stockholder value, including costs and capital structure [7] Management's Comments on Operating Environment and Future Outlook - Management noted that supply chain issues have impacted the ability to fulfill orders, with a backlog of over $9 million [5] - The outlook for the near term is tempered by supply chain reliability concerns [6] - Full-year guidance for total revenue is revised to approximately $123 to $127 million, reflecting ongoing challenges [27] Other Important Information - The company has completed its commitments under the DARPA agreement, recognizing $600 thousand in revenue [22] - The public website has been re-platformed to enhance e-commerce efficiency and distributor relationships [17] Q&A Session Summary - No specific questions or answers were provided in the transcript, as the call concluded with a thank you from management [29]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to _____________________________________________ Commission file number: 001-34180 FLUIDIGM CORPORATION (Exact name ...

Investor Overview September 2021 Legal Information Forward-looking statements This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding revenue growth and profitability targets, consumables and services recurring revenue growth expectations, market opportunities, expense management, productivity and efficiency goals, product innovation, Fluidigm's access ...

Supplemental Financial Information Q2 2021 August 5, 2021 Legal Information Forward-looking statements This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding revenue growth and profitability targets, consumables and services recurring revenue growth expectations, market opportunities, expense management, productivity and efficiency goals, product inno ...

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Financial Statements (unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20%28unaudited%29) The unaudited condensed consolidated financial statements for the period ended June 30, 2021, show a decrease in total assets to $289.3 million from $324.8 million at year-end 2020, primarily due to a reduction in cash and cash equivalents, with net loss widening to $36.0 million despite a 19% year-over-year increase in total revenue to $63.8 million for the six-month period Condensed Consolidated Balance Sheets (in thousands) | | June 30, 2021 | December 31, 2020 | | :--- | :--- | :--- | | **Total current assets** | $78,206 | $117,663 | | **Total assets** | $289,315 | $324,757 | | **Total current liabilities** | $52,848 | $54,249 | | **Total liabilities** | $179,865 | $185,707 | | **Total stockholders' equity** | $109,450 | $139,050 | Condensed Consolidated Statements of Operations (in thousands) | | Three Months Ended June 30, 2021 | Three Months Ended June 30, 2020 | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :--- | :--- | :--- | :--- | :--- | | **Total revenue** | $31,018 | $26,058 | $63,812 | $53,675 | | **Loss from operations** | $(17,268) | $(13,726) | $(36,588) | $(28,668) | | **Net loss** | $(17,143) | $(13,015) | $(35,964) | $(28,995) | | **Net loss per share** | $(0.23) | $(0.18) | $(0.48) | $(0.41) | Condensed Consolidated Statements of Cash Flows (in thousands) | | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :--- | :--- | :--- | | **Net cash used in operating activities** | $(27,565) | $(7,085) | | **Net cash provided by (used in) investing activities** | $(9,095) | $27,586 | | **Net cash provided by (used in) financing activities** | $(1,159) | $8 | | **Net (decrease) increase in cash** | $(37,657) | $20,304 | - The company has a contract with the National Institutes of Health (NIH) under the RADx program with a total value of up to **$34.0 million** to expand production capacity for COVID-19 testing[53](index=53&type=chunk) - As of June 30, 2021, the total value of milestones reasonably assured was **$31.4 million**, with a total deferred grant income of **$28.2 million**[68](index=68&type=chunk)[71](index=71&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=29&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management's analysis of financial results for Q2 and H1 2021 highlights a 19% year-over-year revenue increase for both periods, driven by strong growth in consumables and services, with expectations for lower cash usage in the second half of 2021 despite potential negative impacts on product and service margins due to product transition and mix [Results of Operations](index=31&type=section&id=Results%20of%20Operations) Total revenue grew 19% year-over-year to $31.0 million for Q2 and $63.8 million for H1 2021, driven by a 30% increase in product and service revenue, though product and service margin decreased by 2.4 percentage points to 50.1% due to higher provisions for obsolete inventory and lower average selling prices Revenue by Source (in thousands) | Revenue Source | Three Months Ended June 30, 2021 | YoY Change | | :--- | :--- | :--- | | Instruments | $10,179 | 19% | | Consumables | $12,448 | 41% | | **Product revenue** | **$22,627** | **30%** | | **Service revenue** | **$6,627** | **29%** | | Development revenue | $850 | (72)% | | **Total revenue** | **$31,018** | **19%** | Revenue by Geographic Area (in thousands) | Geographic Area | Three Months Ended June 30, 2021 | YoY Change | | :--- | :--- | :--- | | Americas | $16,120 | 16% | | EMEA | $9,220 | 41% | | Asia-Pacific | $5,678 | 2% | | **Total revenue** | **$31,018** | **19%** | - Product and service margin decreased by **2.4 percentage points** for Q2 2021 compared to Q2 2020, falling to **50.1%**, primarily due to higher provisions for excess and obsolete inventory related to COVID-19 testing consumables, lower average selling prices of mass cytometry instruments, and higher service costs[176](index=176&type=chunk) - Operating expenses increased by **16%** in Q2 2021 compared to Q2 2020, with R&D expenses rising **12%** to **$9.4 million** and SG&A expenses increasing **18%** to **$24.2 million**, driven by higher compensation costs, consulting fees, and travel expenses[178](index=178&type=chunk)[180](index=180&type=chunk)[184](index=184&type=chunk) [Liquidity and Capital Resources](index=37&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2021, the company's principal liquidity sources were $30.9 million in cash and cash equivalents and $10.9 million available under its revolving credit facility, with net cash used in operating activities significantly increasing to $27.6 million for H1 2021, though management believes existing resources are sufficient for at least the next 18 months following a recent credit facility amendment Cash Flow Summary (in thousands) | | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 | | :--- | :--- | :--- | | **Net cash used in operating activities** | $(27,565) | $(7,085) | | **Net cash provided by (used in) investing activities** | $(9,095) | $27,586 | | **Net cash provided by (used in) financing activities** | $(1,159) | $8 | - As of June 30, 2021, principal sources of liquidity consisted of **$30.9 million** of cash and cash equivalents and **$10.9 million** of availability under the Revolving Credit Facility[191](index=191&type=chunk)[213](index=213&type=chunk) - On August 2, 2021, the company amended its credit agreement, extending its **$15.0 million** Revolving Credit Facility to August 2, 2023, and adding a new **$10.0 million** Term Loan Facility, from which the company immediately drew a **$5.0 million** term loan advance[134](index=134&type=chunk)[151](index=151&type=chunk)[208](index=208&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=41&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risks stem from fluctuations in foreign currency exchange rates and interest rates, with a majority of revenue denominated in U.S. dollars while expenses are incurred in various currencies, creating exposure to currency fluctuations, though interest rate risk is considered minimal - The company's results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates, as revenues are primarily in USD while expenses are in multiple currencies, and the company does not currently engage in foreign currency hedging[219](index=219&type=chunk)[220](index=220&type=chunk) - Interest rate risk is considered immaterial, as cash and cash equivalents are held in short-term deposits and money market funds, and a **10%** change in interest rates would not have materially affected interest income[221](index=221&type=chunk) [Controls and Procedures](index=43&type=section&id=Item%204.%20Controls%20and%20Procedures) Based on an evaluation as of June 30, 2021, the company's management, including the CEO and CFO, concluded that its disclosure controls and procedures were effective at a reasonable assurance level, with no material changes in internal control over financial reporting during the quarter - The Chief Executive Officer and Chief Financial Officer concluded that as of June 30, 2021, the company's disclosure controls and procedures were effective at the reasonable assurance level[223](index=223&type=chunk) - There were no changes in the company's internal control over financial reporting during the six months ended June 30, 2021, that have materially affected, or are reasonably likely to materially affect, internal controls[224](index=224&type=chunk) [PART II. OTHER INFORMATION](index=46&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=46&type=section&id=Item%201.%20Legal%20Proceedings) The company is a defendant in a putative class action lawsuit filed in September 2020, alleging violations of federal securities laws, for which the court granted the company's motion to dismiss with leave for the plaintiff to amend on August 4, 2021, and the company intends to vigorously defend the action - A putative class action complaint alleging federal securities law violations was filed against the company in September 2020, and the company's motion to dismiss was granted with leave to amend on August 4, 2021, with the company believing the claims are without merit and intending to defend the action vigorously[131](index=131&type=chunk)[229](index=229&type=chunk) [Risk Factors](index=46&type=section&id=Item%201A.%20Risk%20Factors) The company faces numerous significant risks that could adversely affect its business, including the ongoing impact of the COVID-19 pandemic, a history of incurring net losses, intense competition, reliance on single-source suppliers, potential manufacturing disruptions, the need to retain key personnel, regulatory uncertainty regarding "research use only" products, and financial risks from significant outstanding debt and uncertain future capital needs - The COVID-19 pandemic has significantly affected business operations, causing reduced demand for some products, operational inefficiencies, and supply chain disruptions, and while it created opportunities in diagnostics, the demand for COVID-19 testing products has slowed, leading to lowered revenue expectations for 2021[241](index=241&type=chunk)[242](index=242&type=chunk)[243](index=243&type=chunk) - The company has a history of significant net losses, with an accumulated deficit of **$712.7 million** as of June 30, 2021, and may continue to incur substantial losses for the foreseeable future due to investments in R&D and sales and marketing[251](index=251&type=chunk) - The company relies on single and sole source suppliers for critical components, such as the specialized polymer for IFCs and the electron multiplier detector for Helios/Hyperion systems, and the loss of any of these suppliers could significantly disrupt production[279](index=279&type=chunk)[281](index=281&type=chunk) - The company's products, currently labeled as "research use only" (RUO), could become subject to stricter regulation as medical devices by the FDA, especially if customers use them in laboratory-developed tests (LDTs), and evolving FDA oversight of LDTs could adversely impact sales and require changes to the business model[319](index=319&type=chunk)[320](index=320&type=chunk)[323](index=323&type=chunk) - The company has a significant amount of outstanding debt, including **$55.0 million** of **5.25%** convertible senior notes due 2024, which requires cash flow for interest payments and limits financial flexibility[350](index=350&type=chunk)[354](index=354&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=80&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities during the reporting period - None [Defaults Upon Senior Securities](index=80&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities during the reporting period - None [Mine Safety Disclosures](index=80&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - None [Other Information](index=80&type=section&id=Item%205.%20Other%20Information) The company reported no information required to be disclosed under this item - None [Exhibits](index=81&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including amendments to the NIH contract and lease agreements, new employment terms for an executive, the amended 2011 Equity Incentive Plan, an amendment to the loan and security agreement with Silicon Valley Bank, and required CEO/CFO certifications - The report includes a list of filed exhibits, such as amendments to the NIH contract, lease agreements, management compensation plans, and the Fourth Amendment to the Loan and Security Agreement with Silicon Valley Bank[395](index=395&type=chunk)[397](index=397&type=chunk)

Fluidigm Corporation (FLDM) Q1 2021 Earnings Conference Call May 6, 2021 5:00 PM ET Company Participants Peter DeNardo - Investor Relations Chris Linthwaite - President and Chief Executive Officer Vikram Jog - Chief Financial Officer Conference Call Participants Dan Brennan - UBS Sung Ji Nam - BTIG LLC Operator Good day and thank you for standing by. Welcome to the Fluidigm First Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers' pre ...